05:23 PM EDT, 08/19/2024 (MT Newswires) -- Cue Biopharma ( CUE ) reported a Q2 net loss late Monday of $0.20 per diluted share, narrowing from a loss of $0.29 a year earlier.

Four analysts polled by Capital IQ expected a loss of $0.27.

Revenue for the quarter ended June 30 was $2.7 million, up from $1.4 million a year earlier. Four analysts surveyed by Capital IQ expected $1.3 million.

Cue Biopharma ( CUE ) said its cash and cash equivalents as of June 30 were $30 million down from $48.5 million a year earlier.

Current cash, cash equivalents and marketable securities will fund operations through Q2 2025, according to the company.